Liver transplantation is more widely used in hepatocellular carcinoma (HCC) cases than it is in cholangiocarcinoma (CCA), but both cancers present similar problems and opportunities in terms of earlier diagnosis, more effective treatment options, neoadjuvant therapy and organ allocation, according to this year’s Thomas E. S... Read more

Ongoing advances in stem cell research and genetic technologies have led to important breakthroughs in organoid technology, which holds great promise for aiding in drug development, disease modeling and, ultimately, precision medicine applications, according to Hans Clevers, MD, PhD, who will deliver this year's Hans Popper... Read more

Alanine aminotransferase (ALT) flares are a common feature of hepatitis B (HBV) and are a sensitive indicator of liver injury. Yet not all flares are injurious, according to speakers during the Hepatitis B Special Interest Group session on Sunday. Read more

Clinicians attending Monday afternoon’s “Best Practices in Hepatology 2018” Clinical Practice SIG Program will discover practical advice that will improve everyday patient care. Read more

AASLD’s Diversity Committee is sponsoring an inaugural Diversity Workshop that has been designed to provide a broad overview on racial and ethnic disparities as they pertain to liver disease as well as help define solutions and shape the future direction of the committee’s agenda. Read more

Screening for primary sclerosing cholangitis (PSC)-associated malignancies will likely approve patient outcomes, according to John E. Eaton, MD, gastroenterologist and internist at the Mayo Clinic, Rochester. Read more

While research continues to provide important new insights into drug-induced liver injury (DILI), it remains unclear as to whether patients with chronic liver disease (CLD) are at a higher risk for DILI than patients with healthy livers. That uncertainty has significant implications, not only for clinical care, but also for... Read more

With return-to-drinking rates within five years of transplant hovering around 50 percent in non-acute alcoholic hepatitis patients, incorporating a substance abuse nurse coordinator or addiction team would likely help reduce relapse. Read more

Tuesday’s Leon Schiff State-of-the-Art Lecture is taking on what the lecturer calls “the disease of the day” in hopes of shining a light on unmet needs in the race for a cure of nonalcoholic steatohepatitis (NASH). Read more

With hepatocellular carcinoma (HCC) now the sixth most-common tumor in terms of new cases yearly and the fourth-leading cause of cancer deaths worldwide, The Liver Meeting® has put together a Global Forum dedicated to sharing experiences from different parts of the world to enhance local capabilities in addressing this sign... Read more